News

QuantuMDx Group Ltd has announced plans to expand the potential of its Q-POC™ technology and develop a quality control analytics system for cell and gene therapies (C&GTs), to be evaluated

 To coincide with Cervical Cancer Prevention Week, QuantuMDx Group has announced the start of a field study with St George’s, University of London, to evaluate its human papilloma virus (HPV)

  QuantuMDx Group Limited and Molbio Diagnostics Private Limited have signed a memorandum of understanding (MoU) to explore opportunities for joint working in infectious disease diagnostics, with an initial focus

Next week, world leaders will meet to take part in the first UN High Level Meeting on TB, in history. As QuantuMDx is the only UK company accredited to attend

  QuantuMDx Group Ltd today announced two key leadership appointments. Dr Allan Brown has been appointed Chief Operating Officer and David Matthews joins as Chief Financial Officer. “These appointments represent the

The Consul General of India, Dr Aman Puri, visited Newcastle upon Tyne yesterday which included a tour of laboratories at QuantuMDx Group Limited (QuantuMDx). As a life science tools and diagnostics company, QuantuMDx

QuantuMDx Group has been awarded ISO 13485: 2016 certification – representing the highest standard of quality a medical devices company can achieve. ISO 13485 is a quality system standard designed

Newcastle upon Tyne, UK – 23 January 2018 Life science tools and diagnostics company QuantuMDx announced today it has closed a $12m funding round. As part of this round it

2 February 2017, Newcastle upon Tyne, UK QuantuMDx Group announce an assay co-development and commercialisation agreement with The Global Good Fund, managed by Intellectual Ventures, to develop a rapid, low-cost

15 December 2016, Newcastle upon Tyne QuantuMDx today announced the appointment of CEO Elaine Warburton OBE to the Precision Medicine Catapult Board of Directors as Non Executive Director. Recognised with

28th November 2016, Newcastle upon Tyne, UK QuantuMDx announced today that it received funding from the Bill & Melinda Gates Foundation to further develop and test its CAPTURE-XT™ pathogen concentration